«. Pour-le-groupe and . Témoins, AEA sont décrites à 08h (T max) avec une valeur de 1,20 [1,02-1,30] pmol/ml, soit 141 % [115-147] de la moyenne individuelle. Les concentrations minimales (Cmin) d'AEA sont décrites à 04h avec une valeur de 0, pp.65-65

. La-valeur-moyenne, La valeur à 8h est de 1,13 [1,01-1,19] pmol/ml. La valeur maximale de Cmin est de 1, pp.89-89

Y. Gaoni and R. Mechoulam, Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish, Journal of the American Chemical Society, vol.86, issue.8, pp.1646-1647, 1964.
DOI : 10.1021/ja01062a046

L. Bricaire and T. Brue, Le syst??me endocannabino??de: des effets m??taboliques aux effets neuroendocriniens, Annales d'Endocrinologie, vol.68, issue.1, pp.12-19, 2007.
DOI : 10.1016/S0003-4266(07)80004-7

R. Pertwee and . Endocannabinoids, Disponible sur, Handbook of Experimental Pharmacology, vol.2015, issue.231, pp.978-981, 2016.

L. Matsuda, S. Lolait, M. Brownstein, A. Young, and T. Bonner, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, vol.346, issue.6284, pp.561-565, 1990.
DOI : 10.1038/346561a0

S. Munro, K. Thomas, and M. Abu-shaar, Molecular characterization of a peripheral receptor for cannabinoids, Nature, vol.365, issue.6441, pp.61-66, 1993.
DOI : 10.1038/365061a0

W. Devane, L. Hanus, A. Breuer, R. Pertwee, L. Stevenson et al., Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, vol.258, issue.5090, pp.1946-1955, 1992.
DOI : 10.1126/science.1470919

R. Pertwee, A. Howlett, M. Abood, S. Alexander, D. Marzo et al., International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2, Pharmacological Reviews, vol.62, issue.4, pp.588-631, 2010.
DOI : 10.1124/pr.110.003004

M. Herkenham, A. Lynn, M. Little, M. Johnson, L. Melvin et al., Cannabinoid receptor localization in brain., Proceedings of the National Academy of Sciences, vol.87, issue.5, pp.1932-1936, 1990.
DOI : 10.1073/pnas.87.5.1932

URL : http://www.pnas.org/content/87/5/1932.full.pdf

C. Ziegler, C. Mohn, V. Lamounier-zepter, V. Rettori, S. Bornstein et al., Expression and Function of Endocannabinoid Receptors in the Human Adrenal Cortex, Hormone and Metabolic Research, vol.42, issue.02, pp.88-92, 2010.
DOI : 10.1055/s-0029-1241860

U. Pagotto, G. Marsicano, F. Fezza, M. Theodoropoulou, Y. Grubler et al., Normal Human Pituitary Gland and Pituitary Adenomas Express Cannabinoid Receptor Type 1 and Synthesize Endogenous Cannabinoids: First Evidence for a Direct Role of Cannabinoids on Hormone Modulation at the Human Pituitary Level 1, J Clin Endocrinol Metab, vol.86, issue.6, pp.2687-2696, 2001.

U. Pagotto, G. Marsicano, D. Cota, B. Lutz, and R. Pasquali, The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance, Endocrine Reviews, vol.27, issue.1, pp.73-100, 2006.
DOI : 10.1210/er.2005-0009

R. Mechoulam, S. Ben-shabat, L. Hanus, M. Ligumsky, N. Kaminski et al., Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochemical Pharmacology, vol.50, issue.1, pp.83-90, 1995.
DOI : 10.1016/0006-2952(95)00109-D

T. Freund, I. Katona, and D. Piomelli, Role of Endogenous Cannabinoids in Synaptic Signaling, Physiological Reviews, vol.83, issue.3, pp.1017-66, 2003.
DOI : 10.1152/physrev.00004.2003

D. Piomelli, H. Hansen, and T. Diep, The molecular logic of endocannabinoid signalling N-acylethanolamines, anandamide and food intake, Nat Rev Neurosci. nov Biochem Pharmacol. sept, vol.478, issue.156, pp.553-60, 2003.

L. Hollister, Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine, Clinical Pharmacology & Therapeutics, vol.12, issue.1, pp.44-53, 1971.
DOI : 10.1002/cpt197112144

M. Gagnon and E. R. , Effects of marijuana and D-amphetamine on the appetite, food consumption and various cardio-respiratory variables in man], Union Med Can. juin, vol.104, issue.6, pp.914-935, 1975.

M. Struwe, S. Kaempfer, C. Geiger, A. Pavia, T. Plasse et al., Effect of Dronabinol on Nutritional Status in HIV Infection, Annals of Pharmacotherapy, vol.17, issue.7-8, pp.827-858, 1993.
DOI : 10.1038/231260b0

V. Simon, D. Cota, . Mechanisms, . In, and . Endocrinology, MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future, European Journal of Endocrinology, vol.176, issue.6, pp.309-333, 2017.
DOI : 10.1530/EJE-16-1044

URL : http://www.eje-online.org/content/176/6/R309.full.pdf

C. Silvestri, D. Marzo, and V. , The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders, Cell Metabolism, vol.17, issue.4, pp.475-90, 2013.
DOI : 10.1016/j.cmet.2013.03.001

N. Jamshidi and D. Taylor, Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats, British Journal of Pharmacology, vol.143, issue.6, pp.1151-1154, 2001.
DOI : 10.1097/00024382-200003000-00006

T. Kirkham, C. Williams, F. Fezza, and V. Marzo, Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol, British Journal of Pharmacology, vol.71, issue.4, pp.550-557, 2002.
DOI : 10.1016/S0306-4522(97)00436-3

L. Bellocchio, P. Lafenêtre, A. Cannich, D. Cota, N. Puente et al., Bimodal control of stimulated food intake by the endocannabinoid system, Nature Neuroscience, vol.77, issue.3, pp.281-284, 2010.
DOI : 10.1038/nn.2494

C. Trillou, M. Arnone, C. Delgorge, N. Gonalons, P. Keane et al., Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice, American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, vol.284, issue.2, pp.345-53, 2003.
DOI : 10.1152/ajpregu.00545.2002

D. Cota, G. Marsicano, M. Tschöp, Y. Grübler, C. Flachskamm et al., The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis, Journal of Clinical Investigation, vol.112, issue.3, pp.423-454, 2003.
DOI : 10.1172/JCI17725

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC166293/pdf

T. Melis, S. Succu, F. Sanna, A. Boi, A. Argiolas et al., The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food, Neuroscience Letters, vol.419, issue.3, pp.231-236, 2007.
DOI : 10.1016/j.neulet.2007.04.012

A. Verty, I. Mcgregor, and P. Mallet, The dopamine receptor antagonist SCH 23390 attenuates feeding induced by ??9-tetrahydrocannabinol, Brain Research, vol.1020, issue.1-2, pp.188-95, 2004.
DOI : 10.1016/j.brainres.2004.06.033

D. Luca, M. Solinas, M. Bimpisidis, Z. Goldberg, S. et al., Cannabinoid facilitation of behavioral and biochemical hedonic taste responses, Neuropharmacology, vol.63, issue.1, pp.161-169, 2012.
DOI : 10.1016/j.neuropharm.2011.10.018

S. Lockie, T. Czyzyk, N. Chaudhary, D. Perez-tilve, S. Woods et al., CNS Opioid Signaling Separates Cannabinoid Receptor 1-Mediated Effects on Body Weight and Mood-Related Behavior in Mice, Endocrinology, vol.152, issue.10, pp.3661-3668, 2011.
DOI : 10.1210/en.2011-1220

A. Tallett, J. Blundell, and R. Rodgers, Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats, Pharmacology Biochemistry and Behavior, vol.91, issue.3, pp.358-66, 2009.
DOI : 10.1016/j.pbb.2008.08.007

M. Bensaid, M. Gary-bobo, A. Esclangon, J. Maffrand, L. Fur et al., The Cannabinoid CB1 Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells, Molecular Pharmacology, vol.63, issue.4, pp.908-914, 2003.
DOI : 10.1124/mol.63.4.908

I. Matias, M. Gonthier, P. Orlando, V. Martiadis, D. Petrocellis et al., Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and ??-Pancreatic Cells and in Obesity and Hyperglycemia, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.8, pp.3171-80, 2006.
DOI : 10.1210/jc.2005-2679

I. Matias, T. Bisogno, D. Marzo, and V. , Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake, International Journal of Obesity, vol.258, pp.7-12, 2006.
DOI : 10.1038/nn1457

M. Bouaboula, S. Hilairet, J. Marchand, L. Fajas, G. Fur et al., Anandamide induced PPAR?? transcriptional activation and 3T3-L1 preadipocyte differentiation, European Journal of Pharmacology, vol.517, issue.3, pp.174-81, 2005.
DOI : 10.1016/j.ejphar.2005.05.032

S. Karaliota, A. Siafaka-kapadai, C. Gontinou, K. Psarra, and M. Mavri-vavayanni, Anandamide Increases the Differentiation of Rat Adipocytes and Causes PPAR?? and CB1 Receptor Upregulation, Obesity, vol.131, issue.Suppl 1, pp.1830-1838, 2009.
DOI : 10.1038/sj.bjp.0703569

J. Liu, R. Cinar, K. Xiong, G. Godlewski, J. T. Lin et al., Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase, Proceedings of the National Academy of Sciences, vol.5, issue.4, pp.18832-18839, 2013.
DOI : 10.1073/pnas.0336351100

URL : http://www.pnas.org/content/110/47/18832.full.pdf

D. Osei-hyiaman, M. Depetrillo, P. Pacher, J. Liu, S. Radaeva et al., Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, Journal of Clinical Investigation, vol.115, issue.5, pp.1298-305, 2005.
DOI : 10.1172/JCI200523057

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087161/pdf

D. Osei-hyiaman, J. Liu, L. Zhou, G. Godlewski, J. Harvey-white et al., Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice, Journal of Clinical Investigation, vol.118, issue.9, pp.3160-3169, 2008.
DOI : 10.1172/JCI34827

N. Dipatrizio, G. Astarita, G. Schwartz, X. Li, and D. Piomelli, Endocannabinoid signal in the gut controls dietary fat intake, Proc Natl Acad Sci. 2 août, pp.12904-12912, 2011.
DOI : 10.1016/j.chembiol.2007.10.017

N. Dipatrizio, A. Joslin, K. Jung, and D. Piomelli, Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats, The FASEB Journal, vol.27, issue.6, pp.2513-2533, 2013.
DOI : 10.1096/fj.13-227587

K. Malenczyk, M. Jazurek, E. Keimpema, C. Silvestri, J. Janikiewicz et al., Cannabinoid Receptors Couple to Focal Adhesion Kinase to Control Insulin Release, Journal of Biological Chemistry, vol.29, issue.45, pp.32685-99, 2013.
DOI : 10.1113/jphysiol.2008.157107

URL : http://www.jbc.org/content/288/45/32685.full.pdf

K. Malenczyk, E. Keimpema, F. Piscitelli, D. Calvigioni, P. Björklund et al., Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture, Proceedings of the National Academy of Sciences, vol.34, issue.2, pp.6185-94, 2015.
DOI : 10.1038/372686a0

F. Bermudez-silva, S. Romero-zerbo, M. Haissaguerre, I. Ruz-maldonado, S. Lhamyani et al., The cannabinoid CB1 receptor and mTORC1 signalling pathways interact to modulate glucose homeostasis in mice, Disease Models & Mechanisms, vol.9, issue.1, pp.51-61, 2016.
DOI : 10.1242/dmm.020750

T. Jourdan, G. Godlewski, R. Cinar, A. Bertola, G. Szanda et al., Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes, Nature Medicine, vol.12, issue.9, pp.1132-1172, 2013.
DOI : 10.1074/jbc.M306062200

T. Jourdan, G. Szanda, R. Cinar, G. Godlewski, D. Holovac et al., Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type 2 Diabetes, Diabetes, vol.66, issue.4, pp.994-1007, 2017.
DOI : 10.2337/db16-1199

K. Lindborg, M. Teachey, S. Jacob, and E. Henriksen, Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle, Diabetes, Obesity and Metabolism, vol.141, issue.Suppl 2, pp.722-730, 2010.
DOI : 10.1007/s00213-002-1384-8

C. Lipina, C. Stretton, S. Hastings, J. Hundal, K. Mackie et al., Regulation of MAP Kinase-Directed Mitogenic and Protein Kinase B-Mediated Signaling by Cannabinoid Receptor Type 1 in Skeletal Muscle Cells, Diabetes, vol.59, issue.2, pp.375-385, 2010.
DOI : 10.2337/db09-0979

L. Tedesco, A. Valerio, M. Dossena, A. Cardile, M. Ragni et al., Cannabinoid Receptor Stimulation Impairs Mitochondrial Biogenesis in Mouse White Adipose Tissue, Muscle, and Liver: The Role of eNOS, p38 MAPK, and AMPK Pathways, Diabetes, vol.59, issue.11, pp.2826-2862, 2010.
DOI : 10.2337/db09-1881

P. Freestone, E. Guatteo, F. Piscitelli, V. Di-marzo, J. Lipski et al., Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta, Neuropharmacology, vol.79, pp.467-75, 2014.
DOI : 10.1016/j.neuropharm.2013.12.007

I. Knani, B. Earley, S. Udi, A. Nemirovski, R. Hadar et al., Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader???Willi syndrome, Molecular Metabolism, vol.5, issue.12, pp.1187-99, 2016.
DOI : 10.1016/j.molmet.2016.10.004

R. Motaghedi, E. Lipman, J. Hogg, P. Christos, M. Vogiatzi et al., Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome, European Journal of Medical Genetics, vol.54, issue.1, pp.14-22, 2011.
DOI : 10.1016/j.ejmg.2010.09.015

B. Gatta-cherifi, I. Matias, M. Vallee, A. Tabarin, G. Marsicano et al., Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity, International Journal of Obesity, vol.20, issue.6, p.880, 2012.
DOI : 10.1111/j.1365-2826.2008.01693.x

P. Monteleone, F. Piscitelli, P. Scognamiglio, A. Monteleone, B. Canestrelli et al., Hedonic Eating Is Associated with Increased Peripheral Levels of Ghrelin and the Endocannabinoid 2-Arachidonoyl-Glycerol in Healthy Humans: A Pilot Study, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.6, pp.917-941, 2012.
DOI : 10.1210/jc.2011-3018

A. Monteleone, V. Marzo, P. Monteleone, R. Grave, T. Aveta et al., Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity, European Journal of Nutrition, vol.4, issue.Suppl 2, pp.1799-805, 2016.
DOI : 10.3389/fpsyg.2013.00757

A. Monteleone, V. Marzo, T. Aveta, F. Piscitelli, R. Grave et al., Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa, American Journal of Clinical Nutrition, vol.101, issue.2, pp.262-271, 2015.
DOI : 10.3945/ajcn.114.096164

URL : http://ajcn.nutrition.org/content/101/2/262.full.pdf

M. Bordicchia, I. Battistoni, L. Mancinelli, E. Giannini, G. Refi et al., Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans, Metabolism, vol.59, issue.5, pp.734-775, 2010.
DOI : 10.1016/j.metabol.2009.09.018

T. Baye, Y. Zhang, E. Smith, C. Hillard, J. Gunnell et al., ) is associated with derangements in lipid homeostasis, independent of body mass index, Pharmacogenomics, vol.10, issue.11, pp.1647-56, 2008.
DOI : 10.1375/twin.10.6.805

C. Martins, M. Genelhu, V. Pimentel, M. Celoria, B. Mangia et al., Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic Admixture, PLOS ONE, vol.5, issue.1, 4641669.
DOI : 10.1371/journal.pone.0142728.t004

J. Sipe, T. Scott, S. Murray, O. Harismendy, G. Simon et al., Disponible sur Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects, Biomarkers of Endocannabinoid System Activation in Severe Obesity. PLoS ONE [Internet Eur J Endocrinol. 11 janv, vol.5161, issue.15, pp.715-737, 2009.

J. Cedernaes, F. Fanelli, A. Fazzini, U. Pagotto, J. Broman et al., Sleep restriction alters plasma endocannabinoids concentrations before but not after exercise in humans, Psychoneuroendocrinology, vol.74, pp.258-68, 2016.
DOI : 10.1016/j.psyneuen.2016.09.014

URL : https://doi.org/10.1016/j.psyneuen.2016.09.014

S. Engeli, J. Böhnke, M. Feldpausch, K. Gorzelniak, J. Janke et al., Activation of the Peripheral Endocannabinoid System in Human Obesity, Diabetes, vol.54, issue.10, pp.2838-2843, 2005.
DOI : 10.2337/diabetes.54.10.2838

M. Bluher, S. Engeli, N. Kloting, J. Berndt, M. Fasshauer et al., Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity, Diabetes, vol.55, issue.11, pp.3053-60, 2006.
DOI : 10.2337/db06-0812

I. Matias, B. Gatta-cherifi, A. Tabarin, S. Clark, T. Leste-lasserre et al., Endocannabinoids Measurement in Human Saliva as Potential Biomarker of Obesity, PLoS ONE, vol.7, issue.7, p.42399, 2012.
DOI : 10.1371/journal.pone.0042399.t001

M. Cote, I. Matias, I. Lemieux, S. Petrosino, N. Almeras et al., Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men, International Journal of Obesity, vol.55, issue.Suppl 1, pp.692-66, 2007.
DOI : 10.1016/j.ab.2006.10.039

J. Abdulnour, S. Yasari, R. Rabasa-lhoret, M. Faraj, S. Petrosino et al., Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study, Obesity, vol.12, issue.1, pp.211-217, 2014.
DOI : 10.1111/j.1463-1326.2010.01227.x

URL : http://onlinelibrary.wiley.com/doi/10.1002/oby.20498/pdf

X. Wang, Q. Yu, H. Yue, J. Zhang, S. Zeng et al., Circulating Endocannabinoids and Insulin Resistance in Patients with Obstructive Sleep Apnea, BioMed Research International, vol.2016, 2016.
DOI : 10.1016/j.jsmc.2007.03.009

S. Engeli, M. Blüher, R. Jumpertz, T. Wiesner, H. Wirtz et al., Circulating anandamide and blood pressure in patients with obstructive sleep apnea, Journal of Hypertension, vol.30, issue.12, pp.2345-51, 2012.
DOI : 10.1097/HJH.0b013e3283591595

R. Jumpertz, T. Wiesner, M. Blüher, S. Engeli, S. Bátkai et al., -acyl-ethanolamides in Patients with Sleep Apnea ??? Specific Role of Oleoylethanolamide, Experimental and Clinical Endocrinology & Diabetes, vol.118, issue.09, pp.591-596, 2010.
DOI : 10.1055/s-0030-1253344

A. Quercioli, Z. Pataky, G. Vincenti, V. Makoundou, D. Marzo et al., Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity, European Heart Journal, vol.32, issue.11, pp.1369-78, 2011.
DOI : 10.1093/eurheartj/ehr029

URL : https://academic.oup.com/eurheartj/article-pdf/32/11/1369/7110167/ehr029.pdf

S. Zelber-sagi, S. Azar, A. Nemirovski, M. Webb, Z. Halpern et al., Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease, Obesity, vol.58, issue.1, pp.94-101, 2017.
DOI : 10.1016/j.metabol.2009.05.032

URL : http://onlinelibrary.wiley.com/doi/10.1002/oby.21687/pdf

J. Bass and J. Takahashi, Circadian Integration of Metabolism and Energetics, Science, vol.142, issue.6, pp.1349-54, 2010.
DOI : 10.1016/j.cell.2010.08.016

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756146/pdf

G. Asher and U. Schibler, Crosstalk between Components of Circadian and Metabolic Cycles in Mammals, Cell Metabolism, vol.13, issue.2, pp.125-162, 2011.
DOI : 10.1016/j.cmet.2011.01.006

L. Vaughn, G. Denning, K. Stuhr, H. De-wit, M. Hill et al., Endocannabinoid signalling: has it got rhythm?, British Journal of Pharmacology, vol.26, issue.1, pp.530-573, 2010.
DOI : 10.1152/ajpregu.90669.2008

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2010.00790.x/pdf

E. Hanlon, E. Tasali, R. Leproult, K. Stuhr, E. Doncheck et al., Circadian Rhythm of Circulating Levels of the Endocannabinoid 2-Arachidonoylglycerol Paris: Flammarion médecine-sciences, 220?6. 76. Chanson P, Young J. Traité d'endocrinologie, 2007.

L. Jacobson, Hypothalamic???Pituitary???Adrenocortical Axis Regulation, Endocrinology and Metabolism Clinics of North America, vol.34, issue.2, pp.271-92, 2005.
DOI : 10.1016/j.ecl.2005.01.003

J. Herman, H. Figueiredo, N. Mueller, Y. Ulrich-lai, M. Ostrander et al., Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo???pituitary???adrenocortical responsiveness, Frontiers in Neuroendocrinology, vol.24, issue.3, pp.151-80, 2003.
DOI : 10.1016/j.yfrne.2003.07.001

P. Mormede, A. Foury, P. Barat, J. Corcuff, E. Terenina et al., Molecular genetics of hypothalamic?pituitary?adrenal axis activity and function):127?36. 80. Quigley ME, Yen SS. A mid-day surge in cortisol levels The Postprandial Rise in Plasma Cortisol in Men Is Mediated by Macronutrient-Specific Stimulation of Adrenal and Extra-Adrenal Cortisol Production, ):945?7. 81. Stimson RH, pp.160-168, 1979.
DOI : 10.1111/j.1749-6632.2010.05902.x

M. Lee, P. Pramyothin, K. Karastergiou, and S. Fried, Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1842, issue.3, pp.473-81, 2014.
DOI : 10.1016/j.bbadis.2013.05.029

N. Bazhan and D. Zelena, Food-intake regulation during stress by the hypothalamo-pituitary-adrenal axis, Brain Research Bulletin, vol.95, pp.46-53, 2013.
DOI : 10.1016/j.brainresbull.2013.04.002

H. Shimizu, H. Arima, M. Watanabe, M. Goto, R. Banno et al., Glucocorticoids Increase Neuropeptide Y and Agouti-Related Peptide Gene Expression via Adenosine Monophosphate-Activated Protein Kinase Signaling in the Arcuate Nucleus of Rats, Endocrinology, vol.149, issue.9, pp.4544-53, 2008.
DOI : 10.1210/en.2008-0229

E. Gyengesi, Z. Liu, D. Agostino, G. Gan, G. Horvath et al., Corticosterone Regulates Synaptic Input Organization of POMC and NPY, AgRP Neurons in Adult Mice. Endocrinology. 1 nov, vol.151, issue.11, pp.5395-402, 2010.
DOI : 10.1210/en.2010-0681

URL : https://academic.oup.com/endo/article-pdf/151/11/5395/9009197/endo5395.pdf

M. Dallman, S. Fleur, N. Pecoraro, F. Gomez, H. Houshyar et al., Minireview: Glucocorticoids? Food Intake, Abdominal Obesity, and Wealthy Nations Interaction between Corticosterone and Insulin in Obesity: Regulation of Lard Intake and Fat Stores, Endocrinology. juin Endocrinology. mai, vol.145145, issue.875, pp.2174-85, 2004.

M. Dallman, Stress-induced obesity and the emotional nervous system, Trends in Endocrinology & Metabolism, vol.21, issue.3, pp.159-65, 2010.
DOI : 10.1016/j.tem.2009.10.004

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831158/pdf

R. Rosmond and P. Björntorp, The interactions between hypothalamic-pituitary-adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men, International Journal of Obesity, vol.22, issue.12, pp.1184-96, 1998.
DOI : 10.1038/sj.ijo.0800745

P. Anagnostis, V. Athyros, K. Tziomalos, A. Karagiannis, and D. Mikhailidis, The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.8, pp.2692-701, 2009.
DOI : 10.1210/jc.2009-0370

H. Masuzaki, Y. Ogawa, K. Hosoda, T. Miyawaki, I. Hanaoka et al., Glucocorticoid Regulation of Leptin Synthesis and Secretion in Humans: Elevated Plasma Leptin Levels in Cushing's Syndrome):2542?7. 92. Van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur, J Clin Endocrinol Metab. 1 août J Clin Invest. 1 févr, vol.8239, issue.82, pp.81-93, 1997.

A. Moraitis, T. Block, D. Nguyen, and J. Belanoff, The role of glucocorticoid receptors in metabolic syndrome and psychiatric illness, The Journal of Steroid Biochemistry and Molecular Biology, vol.165, pp.114-134, 2017.
DOI : 10.1016/j.jsbmb.2016.03.023

C. Loerz and E. Maser, The cortisol-activating enzyme 11??-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome, The Journal of Steroid Biochemistry and Molecular Biology, vol.174, 2017.
DOI : 10.1016/j.jsbmb.2017.07.030

E. Rask, B. Walker, S. Söderberg, D. Livingstone, M. Eliasson et al., Tissue-Specific Changes in Peripheral Cortisol Metabolism in Obese Women: Increased Adipose 11??-Hydroxysteroid Dehydrogenase Type 1 Activity, The Journal of Clinical Endocrinology & Metabolism, vol.87, issue.7, pp.3330-3336, 2002.
DOI : 10.1210/jcem.87.7.8661

A. Lacroix, R. Feelders, C. Stratakis, and L. Nieman, Cushing's syndrome, The Lancet, vol.386, issue.9996, pp.913-940, 2015.
DOI : 10.1016/S0140-6736(14)61375-1

S. Morgan, Z. Hassan-smith, G. Lavery, S. Pulgar, A. Kempel et al., MECHANISMS IN ENDOCRINOLOGY: Tissue-specific activation of cortisol in Cushing's syndrome The burden of Cushing's disease: clinical and health-related quality of life aspects, R81?7. 98. Feelders RA, pp.311-337, 2012.

A. Rockall, S. Sohaib, D. Evans, G. Kaltsas, A. Isidori et al., Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome, European Journal of Endocrinology, vol.149, issue.6, pp.561-567, 2003.
DOI : 10.1530/eje.0.1490561

P. Chanson and S. Salenave, Metabolic Syndrome in Cushing???s Syndrome, Neuroendocrinology, vol.92, issue.1, pp.96-101, 2010.
DOI : 10.1159/000314272

F. Ferraù and M. Korbonits, Metabolic comorbidities in Cushing's syndrome, European Journal of Endocrinology, vol.173, issue.4, pp.133-57, 2015.
DOI : 10.1530/EJE-15-0354

R. Giordano, F. Guaraldi, R. Berardelli, I. Karamouzis, D. Angelo et al., Glucose metabolism in patients with subclinical Cushing???s syndrome, Endocrine, vol.95, issue.Suppl 1, pp.415-438, 2012.
DOI : 10.1210/jc.2009-2453

B. Kahn, T. Alquier, D. Carling, and D. Hardie, AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism, Cell Metabolism, vol.1, issue.1, pp.15-25, 2005.
DOI : 10.1016/j.cmet.2004.12.003

B. Kola, M. Christ-crain, F. Lolli, G. Arnaldi, G. Giacchetti et al., Changes in Adenosine 5???-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing???s Syndrome, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.12, pp.4969-73, 2008.
DOI : 10.1210/jc.2008-1297

M. Christ-crain, B. Kola, F. Lolli, C. Fekete, D. Seboek et al., AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome, The FASEB Journal, vol.22, issue.6, pp.1672-83, 2008.
DOI : 10.1096/fj.07-094144

M. Starkman, Neuropsychiatric Findings in Cushing Syndrome and Exogenous Glucocorticoid Administration, Endocrinology and Metabolism Clinics of North America, vol.42, issue.3, pp.477-88, 2013.
DOI : 10.1016/j.ecl.2013.05.010

B. Berthon, L. Macdonald-wicks, and L. Wood, A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans, Nutrition Research, vol.34, issue.3, pp.179-90, 2014.
DOI : 10.1016/j.nutres.2013.12.006

M. Starkman, D. Schteingart, and A. Schork, Depressed Mood and Other Psychiatric Manifestations of Cushing??s Syndrome: Relationship to Hormone Levels, Psychosomatic Medicine, vol.43, issue.1, pp.3-18, 1981.
DOI : 10.1097/00006842-198102000-00002

E. Geer, Y. Lalazar, L. Couto, V. Cohen, L. Lipton et al., A prospective study of appetite and food craving in 30 patients with Cushing???s disease, Pituitary, vol.11, issue.3, pp.117-143, 2016.
DOI : 10.1038/nm1201

P. Tataranni, D. Larson, S. Snitker, J. Young, J. Flatt et al., Effects of glucocorticoids on energy metabolism and food intake in humans, Am J Physiol. août, vol.271, issue.2, pp.317-325, 1996.

S. Moeller, L. Couto, V. Cohen, Y. Lalazar, I. Makotkine et al., Glucocorticoid Regulation of Food-Choice Behavior in Humans: Evidence from Cushing's Syndrome, Frontiers in Neuroscience, vol.34, issue.7
DOI : 10.1016/j.psyneuen.2009.03.018

T. Mancini, B. Kola, F. Mantero, M. Boscaro, and G. Arnaldi, High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines, Clinical Endocrinology, vol.29, issue.6, pp.768-77, 2004.
DOI : 10.1046/j.1365-2796.2000.00609.x

R. Clayton, D. Raskauskiene, R. Reulen, and P. Jones, Mortality and Morbidity in Cushing's Disease over 50 Years in Stoke-on-Trent, UK: Audit and Meta-Analysis of Literature, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.3, pp.632-674, 2011.
DOI : 10.1210/jc.2010-1942

Z. Hassan-smith, M. Sherlock, R. Reulen, W. Arlt, J. Ayuk et al., Outcome of Cushing's Disease following Transsphenoidal Surgery in a Single Center over 20 Years, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.4, pp.1194-201, 2012.
DOI : 10.1210/jc.2011-2957

D. Graversen, P. Vestergaard, K. Stochholm, C. Gravholt, and J. Jørgensen, Mortality in Cushing's syndrome: A systematic review and meta-analysis, European Journal of Internal Medicine, vol.23, issue.3, pp.278-82, 2012.
DOI : 10.1016/j.ejim.2011.10.013

O. Dekkers, N. Biermasz, A. Pereira, F. Roelfsema, V. Aken et al., Mortality in Patients Treated for Cushing???s Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.3, pp.976-81, 2007.
DOI : 10.1210/jc.2006-2112

O. Dekkers, E. Horváth-puhó, J. Jørgensen, S. Cannegieter, V. Ehrenstein et al., Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.6, pp.2277-84, 2013.
DOI : 10.1210/jc.2012-3582

F. Haalen, . Van, L. Broersen, J. Jorgensen, A. Pereira et al., MANAGEMENT OF ENDOCRINE DISEASE: Mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis, European Journal of Endocrinology, vol.172, issue.4, pp.143-152, 2015.
DOI : 10.1530/EJE-14-0556

J. Lambert, L. Goldberg, S. Fayngold, J. Kostadinov, K. Post et al., Predictors of Mortality and Long-term Outcomes in Treated Cushing's Disease: A Study of 346 Patients, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.3, pp.1022-1052, 2013.
DOI : 10.1210/jc.2012-2893

R. Clayton, P. Jones, R. Reulen, P. Stewart, Z. Hassan-smith et al., Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study, The Lancet Diabetes & Endocrinology, vol.4, issue.7, pp.569-76, 2016.
DOI : 10.1016/S2213-8587(16)30005-5

W. Arlt and B. Allolio, Adrenal insufficiency. The Lancet. 31 mai, pp.1881-93, 2003.

S. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-wauchope et al., Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.2, pp.364-89, 2016.
DOI : 10.1210/jc.2015-1710

URL : https://academic.oup.com/jcem/article-pdf/101/2/364/16607579/jcem0364.pdf

A. Debons, K. Das, B. Fuhr, and E. Siclari, Anorexia after Adrenalectomy in Gold Thioglucose-Treated Obese Mice*, Endocrinology, vol.112, issue.5, pp.1847-51, 1983.
DOI : 10.1210/endo-112-5-1847

H. Filipsson, J. Monson, M. Koltowska-häggström, A. Mattsson, and G. Johannsson, The Impact of Glucocorticoid Replacement Regimens on Metabolic Outcome and Comorbidity in Hypopituitary Patients, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.10, pp.3954-61, 2006.
DOI : 10.1210/jc.2006-0524

M. Sherlock, J. Ayuk, J. Tomlinson, A. Toogood, A. Aragon-alonso et al., Mortality in Patients with Pituitary Disease, Endocrine Reviews, vol.31, issue.3, pp.301-343, 2010.
DOI : 10.1210/er.2009-0033

URL : https://academic.oup.com/edrv/article-pdf/31/3/301/10335111/edrv0301.pdf

T. Zueger, P. Kirchner, C. Herren, S. Fischli, M. Zwahlen et al., Glucocorticoid Replacement and Mortality in Patients with Nonfunctioning Pituitary Adenoma, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.10, pp.1938-1980, 2012.
DOI : 10.1210/jc.2012-2432

URL : https://academic.oup.com/jcem/article-pdf/97/10/E1938/10782240/jcem1938.pdf

C. Hammarstrand, O. Ragnarsson, T. Hallén, E. Andersson, T. Skoglund et al., Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma, European Journal of Endocrinology, vol.177, issue.3, pp.251-257, 2017.
DOI : 10.1530/EJE-17-0340

K. Danilowicz, O. Bruno, M. Manavela, R. Gomez, and A. Barkan, Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study, Pituitary, vol.87, issue.3, pp.279-85, 2008.
DOI : 10.7326/0003-4819-133-2-200007180-00010

G. Johannsson, R. Bergthorsdottir, A. Nilsson, H. Lennernas, T. Hedner et al., Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study, European Journal of Endocrinology, vol.161, issue.1, pp.119-149, 2009.
DOI : 10.1530/EJE-09-0170

URL : http://www.eje-online.org/content/161/1/119.full.pdf

G. Johannsson, A. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist et al., Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.2, pp.473-81, 2012.
DOI : 10.1210/jc.2011-1926

A. Hohmann and M. Herkenham, Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study, Neuroscience, vol.90, issue.3, pp.923-931, 1999.
DOI : 10.1016/S0306-4522(98)00524-7

S. Galiègue, S. Mary, J. Marchand, D. Dussossoy, D. Carrière et al., Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations, European Journal of Biochemistry, vol.23, issue.1, pp.54-61, 1995.
DOI : 10.1016/0165-3806(93)90124-S

M. Steiner and C. Wotjak, Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis, Prog Brain Res. 1 janv, vol.170, pp.397-432, 2008.
DOI : 10.1016/S0079-6123(08)00433-0

M. Puder, J. Weidenfeld, I. Chowers, I. Nir, N. Conforti et al., Corticotrophin and corticosterone secretion following ??1-tetrahydrocannabinol, in intact and in hypothalamic deafferentated male rats, Experimental Brain Research, vol.21, issue.1, pp.85-93, 1982.
DOI : 10.1159/000122526

J. Weidenfeld, S. Feldman, and R. Mechoulam, Effect of the Brain Constituent Anandamide, a Cannabinoid Receptor Agonist, on the Hypothalamo-Pituitary-Adrenal Axis in the Rat, Neuroendocrinology, vol.59, issue.2, pp.110-112, 1994.
DOI : 10.1159/000126646

J. Manzanares, J. Corchero, and J. Fuentes, Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of ??9-tetrahydrocannabinol in rats, Brain Research, vol.839, issue.1, pp.173-182, 1999.
DOI : 10.1016/S0006-8993(99)01756-4

J. Martín-calderón, R. Muñoz, M. Villanúa, I. Del-arco, J. Moreno et al., Characterization of the acute endocrine actions of (???)-11-hydroxy-??8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats, European Journal of Pharmacology, vol.344, issue.1, pp.77-86, 1998.
DOI : 10.1016/S0014-2999(97)01560-4

B. Zenor, G. Weesner, and P. Malven, Endocrine and other responses to acute administration of cannabinoid compounds to non-stressed male calves, Life Sciences, vol.65, issue.2, pp.125-158, 1999.
DOI : 10.1016/S0024-3205(99)00229-5

S. Patel, C. Roelke, D. Rademacher, W. Cullinan, and C. Hillard, Endocannabinoid Signaling Negatively Modulates Stress-Induced Activation of the Hypothalamic-Pituitary-Adrenal Axis, Endocrinology, vol.145, issue.12, pp.5431-5439, 2004.
DOI : 10.1210/en.2004-0638

D. Cota, M. Steiner, G. Marsicano, C. Cervino, J. Herman et al., Requirement of Cannabinoid Receptor Type 1 for the Basal Modulation of Hypothalamic-Pituitary-Adrenal Axis Function, Endocrinology, vol.148, issue.4, pp.1574-81, 2007.
DOI : 10.1210/en.2005-1649

M. Ranganathan, G. Braley, B. Pittman, T. Cooper, E. Perry et al., The effects of cannabinoids on serum cortisol and prolactin in humans, Psychopharmacology, vol.46, issue.10, p.737, 2009.
DOI : 10.1002/j.1552-4604.2002.tb06008.x

D. Souza, D. Perry, E. Macdougall, L. Ammerman, Y. Cooper et al., The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis, Neuropsychopharmacology, vol.76, issue.Suppl 3, pp.1558-72, 2004.
DOI : 10.1007/BF00432554

D. Souza, D. Abi-saab, W. Madonick, S. Forselius-bielen, K. Doersch et al., Delta-9- tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction, Biol Psychiatry. 15 mars, vol.57, issue.6, pp.594-608, 2005.

M. Hill, W. Ho, S. Meier, B. Gorzalka, and C. Hillard, Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala, European Journal of Pharmacology, vol.528, issue.1-3, pp.99-102, 2005.
DOI : 10.1016/j.ejphar.2005.10.058

M. Hill, E. Carrier, W. Ho, L. Shi, S. Patel et al., Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus, Hippocampus, vol.141, issue.2, pp.221-227, 2008.
DOI : 10.1002/hipo.20386

M. Hill, I. Karatsoreos, C. Hillard, and B. Mcewen, Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo, Psychoneuroendocrinology, vol.35, issue.9, pp.1333-1341, 2010.
DOI : 10.1016/j.psyneuen.2010.03.005

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914801/pdf

N. Bowles, I. Karatsoreos, X. Li, V. Vemuri, J. Wood et al., A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome, Proceedings of the National Academy of Sciences, vol.46, issue.2, pp.285-90, 2015.
DOI : 10.1021/ac0624086

URL : http://www.pnas.org/content/112/1/285.full.pdf

M. Scerif, T. Füzesi, J. Thomas, B. Kola, A. Grossman et al., CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus, Journal of Endocrinology, vol.219, issue.1, pp.79-88, 2013.
DOI : 10.1530/JOE-13-0192

E. Heyman, F. Gamelin, M. Goekint, F. Piscitelli, B. Roelands et al., Intense exercise increases circulating endocannabinoid and BDNF levels in humans???Possible implications for reward and depression, Psychoneuroendocrinology, vol.37, issue.6, pp.844-51, 2012.
DOI : 10.1016/j.psyneuen.2011.09.017

E. Valassi, I. Crespo, A. Santos, and S. Webb, Clinical consequences of Cushing???s syndrome, Pituitary, vol.130, issue.3, pp.319-348, 2012.
DOI : 10.7326/0003-4819-130-10-199905180-00015

L. Nieman, B. Biller, J. Findling, J. Newell-price, M. Savage et al., The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.5, pp.1526-1566, 2008.
DOI : 10.1210/jc.2008-0125

D. Richardson, C. Ortori, V. Chapman, D. Kendall, and D. Barrett, Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography???tandem electrospray ionization mass spectrometry, Analytical Biochemistry, vol.360, issue.2, pp.216-242, 2007.
DOI : 10.1016/j.ab.2006.10.039

D. Matthews, J. Hosker, A. Rudenski, B. Naylor, D. Treacher et al., Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, vol.92, issue.7, pp.412-421, 1985.
DOI : 10.1007/BF00280883

A. Faggiano, R. Pivonello, S. Spiezia, D. Martino, M. Filippella et al., Cardiovascular Risk Factors and Common Carotid Artery Caliber and Stiffness in Patients with Cushing???s Disease during Active Disease and 1 Year after Disease Remission, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.6, pp.2527-2560, 2003.
DOI : 10.1210/jc.2002-021558

URL : https://academic.oup.com/jcem/article-pdf/88/6/2527/9149720/jcem2527.pdf

N. Bowles, M. Hill, S. Bhagat, I. Karatsoreos, C. Hillard et al., Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice, Neuroscience, vol.204, pp.83-92, 2012.
DOI : 10.1016/j.neuroscience.2011.08.048

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697830/pdf

J. Wamsteeker, J. Kuzmiski, and J. Bains, Repeated Stress Impairs Endocannabinoid Signaling in the Paraventricular Nucleus of the Hypothalamus, Journal of Neuroscience, vol.30, issue.33, pp.11188-96, 2010.
DOI : 10.1523/JNEUROSCI.1046-10.2010

G. Schelling, D. Hauer, S. Azad, M. Schmoelz, A. Chouker et al., Effects of General Anesthesia on Anandamide Blood Levels in Humans, Anesthesiology, vol.104, issue.2, pp.273-280, 2006.
DOI : 10.1097/00000542-200602000-00012

C. Jarzimski, M. Karst, A. Zoerner, C. Rakers, M. May et al., Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol?, British Journal of Clinical Pharmacology, vol.5, issue.884, pp.54-63, 2012.
DOI : 10.1371/journal.pone.0010752